[Tanvex-KY] Announcement of Endorsement/Guarantee Pursuant to Article 25, Paragraph 1, Item 4 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

1. Date of occurrence: 2026/04/22 2. The company provided with endorsement/guarantee: (1) Company name: Tanvex BioPharma USA, Inc. (2) Relationship with the endorsing/guaranteeing company: 100% directly owned subsidiary (3) Limit of endorsement/guarantee (thousands NTD): 579,634 (4) Original balance of endorsement/guarantee (thousands NTD): 0 (5) Amount of newly added endorsement/guarantee (thousands NTD): 479,925 (6) Balance of endorsement/guarantee up to the date of occurrence (thousands NTD): 479,925 (7) Actual utilized amount by the guaranteed company (thousands NTD): 0 (8) Reason for newly added endorsement/guarantee: Providing financing guarantee for subsidiary Tanvex BioPharma USA, Inc. 3. Collateral provided by the guaranteed company: (1) Content: None (2) Value (thousands NTD): 0 4. Latest financial statements of the guaranteed company: (1) Capital (thousands NTD): 17,310,307 (2) Accumulated profit/loss (thousands NTD): -17,185,204 5. Conditions for lifting endorsement/guarantee liability: (1) Conditions: As per contract terms (2) Date: As per contract terms 6. Total limit of endorsement/guarantee (thousands NTD): 1,159,268 7. Balance of endorsement/guarantee up to the date of occurrence (thousands NTD): 479,925 8. Ratio of endorsement/guarantee balance to the net worth of the latest financial statements: 8.28% 9. Ratio of total endorsement/guarantee, long-term investment, and loans to the net worth of the latest financial statements: 8.28% 10. Other matters to be specified: None